Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01207492 Phase II Nilotinib Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Active, not recruiting USA 0
NCT02471716 Phase Ib/II Cabiralizumab Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor Completed USA | FRA 4
NCT02673736 Phase I AC708 A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor Terminated USA 0
NCT04526704 FDA approved Pexidartinib Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib (PLX3397) Active, not recruiting USA | ITA | ESP 4
NCT04938180 Phase II AMG 820 A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients Active, not recruiting DEU 2
NCT05059262 Phase III Vimseltinib Phase 3 Study of Vimseltinib for Tenosynovial Giant Cell Tumor (MOTION) Recruiting USA | ITA | FRA | ESP | DEU | CAN 7
NCT05417789 Phase III Emactuzumab Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) (TANGENT) Active, not recruiting USA 0